N@N

HGSI, AMED, ENER, KOOL, OSUR, ILMN Expected To Be Down Before Next Earnings Releases

January 17, 2012 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released in the coming weeks and determining how the stocks have performed Before their last 12 quarterly, 6 quarterly and June earnings reports. HUMAN GENOME SCIENCES INC (NASDAQ:HGSI), AMEDISYS INC (NASDAQ:AMED), ENERGY CONVERSION DEVICES (NASDAQ:ENER), THERMOGENESIS CORP (NASDAQ:KOOL), ORASURE TECHNOLOGIES INC (NASDAQ:OSUR), ILLUMINA INC (NASDAQ:ILMN) are all expected to be Down Before their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go Down Before earnings are released Thursday:

     Symbol     Company                             # of Reports            Quarter     Release Date
     HGSI       HUMAN GENOME SCIENCES INC           6 Quarter               Q4          02/23/2012
     AMED       AMEDISYS INC                        6 Quarter               Q4          02/21/2012
     ENER       ENERGY CONVERSION DEVICES           12 Quarter              Q2          02/09/2012
     KOOL       THERMOGENESIS CORP                  12 Quarter              Q2          02/09/2012
     OSUR       ORASURE TECHNOLOGIES INC            6 Quarter               Q4          02/08/2012
     ILMN       ILLUMINA INC                        12 Quarter              Q4          02/07/2012

This technology is designed to help the stock trader identify those companies that seem to have a consistent pattern of movement before or after the earnings release date, based on the history of earnings releases for that company. It combines a calendar of expected earnings releases with a history of past earnings releases in a way that lets you see if a pattern exists.

HUMAN GENOME SCIENCES INC (NASDAQ:HGSI) - Human Genome Sciences, Inc. operates as a biopharmaceutical company. Its principal products in development include BENLYSTA for systemic lupus erythematosus; and raxibacumab for inhalation anthrax. The companys mid- and early-stage pipeline products comprise Mapatumumab for the treatment of non-small cell lung cancer, multiple myeloma, and hepatocellular cancer; IAP Inhibitors that are compounds, which block the activity of IAP (inhibitor of apoptosis) proteins, allowing apoptosis to proceed and causing the cancer cells to die; and CCR5 mAb, a human monoclonal antibody to the CCR5 receptor for the treatment of ulcerative colitis. Human Genome Sciences, Inc. also holds financial rights to certain products in the GlaxoSmithKline clinical development pipeline, including darapladib, a Phase III clinical trial product for the treatment of coronary heart disease and ischemic stroke; and Albiglutide for the treatment for type 2 diabetes, which is in Phase III clinical trial stage. The company has a license agreement with GlaxoSmithKline for the co-development and commercialization of BENLYSTA; and a collaboration and license agreement with Aegera Therapeutics, Inc. to develop and commercialize certain oncology molecules and related backup compounds. Human Genome Sciences, Inc. was founded in 1992 and is headquartered in Rockville, Maryland.

AMEDISYS INC (NASDAQ:AMED) - Amedisys Inc. provides home health and hospice services including practical nursing services and physical and occupational therapy. The companys services also comprise speech pathology, social work to help families address acute and chronic illnesses, home health aide services, and private duty services. Hospice services use a team made up of a physician, patient care manager, registered nurses, certified home health aides, social workers, a chaplain, a homemaker, and volunteers. As of Apr. 4, 2007, the company operated 261 Medicare-certified home health agencies and 14 Medicare-certified hospice agencies in 19 states. Amedisys was founded in 1982 and is headquartered in Baton Rouge, La.

ENERGY CONVERSION DEVICES (NASDAQ:ENER) - Energy Conversion Devices, Inc. engages in the design, manufacture, and sale of photovoltaic (PV) products. The company operates in two segments, United Solar Ovonic and Ovonic Materials. The United Solar Ovonic segment provides PV laminates that generate clean and renewable energy by converting sunlight into electricity. It also involves in the design, development, and installation of rooftop and BIPV systems and applications. Its products are used in rooftop and building integrated applications. This segment offers its products to commercial roofing materials manufacturers, builders and building contractors, and solar power installers/integrators. The Ovonic Materials segment invents, designs, develops, and licenses materials and products based on the companys materials science technology. This segment also commercializes the NiMH materials and consumer battery technology. The company operates in the United States, Germany, France, Italy, South Korea, Japan, Hong Kong, and China. Energy Conversion Devices, Inc. was founded in 1960 and is headquartered in Rochester Hills, Michigan.

THERMOGENESIS CORP (NASDAQ:KOOL) - ThermoGenesis Corp. operates as a supplier of products targeting the worldwide adult stem cell market. It offers automated and semi-automated devices, and single-use processing disposables that enable the collection, processing, and cryopreservation of stem cells and other cellular tissues from cord blood and bone marrow used in the practice of regenerative medicine. Regenerative medicine is a field that aims to repair or restore lost or damaged tissue and cell function using cell-based therapies. The companys core offerings include the AXP AutoXpress Platform for processing of cord blood; and BioArchive System, an automated cryogenic device used by cord blood banks for the cryopreservation and archiving of cord blood stem cell units for transplant. Its offerings also comprise MXP MarrowXpress, which is used for isolating stem cells from bone marrow, and the Res-Q 60 BMC, a point-of-care bone marrow stem cell processing system. In addition, ThermoGenesis markets the Thermoline product line, which includes the ultra-rapid plasma Thermoline Freezer and Thermoline Thawer. The company was founded in 1986 and is headquartered in Rancho Cordova, California.

ORASURE TECHNOLOGIES INC (NASDAQ:OSUR) - OraSure Technologies, Inc. develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices. Its products include OraQuick ADVANCE HIV-1/2, a point-of-care test for antibodies to the human immunodeficiency virus type 1 and type 2; OraQuick HCV, a point-of-care test for antibodies to the hepatitis C virus; OraSure, an oral fluid collection device for the detection of antibodies to HIV-1; and Intercept, an oral fluid collection device for oral fluid drugs of abuse testing. The company also offers MICRO-PLATE DOA Assays used to detect drugs in an oral fluid sample; Cryosurgical SystemsProfessional under the Histofreezer trade name for the removal of warts and other benign skin lesions; and Cryosurgical SystemsOTC for the removal of common and plantar warts. In addition, it develops OraQuick HIV-1/2 OTC, a point-of-care oral fluid HIV-1/2 test; Homogeneous DOA Assays; and OraQuick, a point-of-care testing platform. Further, the company sells immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid western blot HIV-1 confirmatory test; and Q.E.D., a rapid point-of-care saliva alcohol test. Additionally, it offers various diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types, and other medical devices used for the removal of benign skin lesions by cryosurgery or freezing. The company markets its products through direct sales, strategic collaborations, and independent distributors to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians offices, and commercial and industrial entities in the United States and internationally. It has collaboration agreements with Merck & Co. Inc. and Roche Diagnostics. The company was founded in 1979 and is based in Bethlehem, Pennsylvania.

ILLUMINA INC (NASDAQ:ILMN) - Illumina, Inc. develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. Its instrumentation products include HiSeq 2000, an instrument for high-throughput (up to 200 Gb per run and up to 25 GB per day) sequencing using sequencing-by-synthesis (SBS) technology; Genome Analyzer IIx, an instrument for medium to high-throughput (up to 95 Gb per run) sequencing using SBS technology; Genome Analyzer IIe, an instrument for low to medium throughput (up to 40 Gb per run) sequencing using SBS technology; iScan System, a high-resolution imaging instrument to scan BeadArray based assays; and BeadXpress Reader, a low- to mid-multiplex, high-throughput instrument for readout of assays. The companys consumables consist of InfiniumHD Whole-Genome BeadChips comprising HumanOmniExpress, HumanOmni1-Quad, Human1M-Duo, and BovineHD, which are multi-sample DNA analysis microarrays; iSelect Custom Genotyping BeadChips that are customer designable SNP genotyping arrays; GoldenGate Assay Method, a high throughput assay and genotyping system; GoldenGate Universal-32 Sample BeadChip, which are 32 sample GoldenGate genotyping arrays; Paired-End Genomic DNA Sample Prep Kit, a streamlined library preparation kit to generate 200500 kb insert paired-end reads; VeraCode GoldenGate that are low plex GoldenGate genotyping arrays compatible with the BeadXpress System; Standard Sequencing Kit, reagents used for SBS chemistry on sequencing platforms; and Infinium Assay Kit, reagents used to perform Infinium assays on the iScan platform. It also provides sequencing and genotyping services. The companys customers include pharmaceutical, biotechnology, agrichemical, diagnostics, and consumer products companies, as well as research centers. It sells its products through distributors in North America, Europe, the Asia-Pacific, the Middle East, and South Africa. Illumina was founded in 1998 and is headquartered in San Diego, California.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com

www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.

INVESTMENTS & TRADING

SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

About SQUEEZETRIGGER.COM

WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.

SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.

Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.squeezetrigger.com +1-800-715-9999 Tom@squeezetrigger.com

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641